Vogenx

Vogenx Announces Positive Results From Second Phase 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia

Vogenx Completes Dosing of Last Patient in Phase 2 Clinical Study of Mizagliflozin for the Treatment of Post-Bariatric Hypoglycemia

Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin for Post-Bariatric Hypoglycemia

Vogenx Announces Initiation of Phase 2 Clinical Study of Mizagliflozin for Post-Bariatric Hypoglycemia

Vogenx Announces Positive Results in Phase 2 Study of Mizagliflozin in Post-Bariatric Hypoglycemia

Vogenx to Present New Phase 2 Clinical Data on Mizagliflozin at the Endocrine Society (ENDO) 2023 Annual Conference

Vogenx Announces Completion of Phase 2 Clinical Study of Mizagliflozin for Post Bariatric Hypoglycemia

Vogenx Announces Initiation of Phase 2 Clinical Study of Mizagliflozin for Post Bariatric Hypoglycemia